Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MET receptor tyrosine kinase as a therapeutic anticancer target.

Cancer letters - 18 Jul 2009

Stellrecht Christine M, Gandhi Varsha

Abstract excerpt

Tyrosine kinases are frequently deregulated in cancer either by constitutive activation, mutation, or over-expression. Though they are often associated with an aggressive phenotype they are also proving to be a druggable target. Activation of the MET receptor tyrosine kinase promotes cell proliferation, scattering, invasion, survival, and angiogenesis. Deregulation of MET promotes tumor formation, growth,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neovascularization, Pathologic
Share to Oncogenes
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Medical Oncology

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins c-met

Share to Receptors, Growth Factor

Source

Identifiers

PMID: 19100682
DOI: 10.1016/j.canlet.2008.10.045

Genes

MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MET receptor tyrosine kinase as a therapeutic anticancer target.PMID 19100682Read ↗

The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.Semantic proximity Read ↗

Receptor Tyrosine Kinases as Therapeutic Targets the Model of the MET OncogeneSemantic proximity Read ↗

Targeting MET Dysregulation in CancerSemantic proximity Read ↗

Cancer therapy: can the challenge be MET?Semantic proximity Read ↗

Targeting the c-MET signaling pathway for cancer therapySemantic proximity Read ↗

MET-dependent solid tumours - molecular diagnosis and targeted therapy.Semantic proximity Read ↗

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.Semantic proximity Read ↗

MET Activation in Lung Cancer and Response to Targeted TherapiesSemantic proximity Read ↗

MET: a new promising biomarker in non-small-cell lung carcinoma.Semantic proximity Read ↗

Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies.Semantic proximity Read ↗

MET alterations in advanced non-small cell lung cancer.Semantic proximity Read ↗

Targeting mesenchymal-epithelial transition factor signaling in cancer: from genetic alterations to clinical advances and future prospects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.